TTPH Quote Trading Chart Tetraphase Pharmaceuticals Inc.

$2.20 Last:

-3.51% Change Percent:

$2.24 Open:

$2.20 Previous Close:

$2.27 High:

$2.18 Low:

279,969 Volume:

07/28/2020 04:56:12 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2020-07-28	2.24	2.2	2.27	2.18	279,969
2020-07-27	2.38	2.28	2.44	2.1703	501,384
2020-07-24	2.28	2.38	2.4	2.27	373,882
2020-07-23	2.38	2.28	2.4217	2.23	273,150
2020-07-22	2.45	2.4	2.48	2.37	95,969
2020-07-21	2.5	2.47	2.55	2.42	119,349
2020-07-20	2.5	2.5199	2.5228	2.45	25,636
2020-07-17	2.51	2.55	2.56	2.5	64,509
2020-07-16	2.43	2.51	2.54	2.41	58,530
2020-07-15	2.4	2.46	2.49	2.38	62,169
2020-07-14	2.36	2.39	2.45	2.36	98,530
2020-07-13	2.47	2.405	2.47	2.3474	107,996
2020-07-10	2.46	2.43	2.48	2.4201	54,709
2020-07-09	2.52	2.48	2.59	2.42	123,205
2020-07-08	2.6	2.53	2.6	2.52	40,391
2020-07-07	2.41	2.58	2.66	2.4	254,419
2020-07-06	2.46	2.44	2.498	2.4101	129,699
2020-07-03	2.54	2.46	2.56	2.4	228,151
2020-07-02	2.54	2.46	2.56	2.4	227,851
2020-07-01	2.51	2.56	2.56	2.495	70,290

Stock Information

Tetraphase Pharmaceuticals Inc. Company Name:

TTPH Stock Symbol:

NASDAQ Market:

TTPH Quote Trading Chart Tetraphase Pharmaceuticals Inc.

Get TTPH Alerts

News, Short Squeeze, Breakout and More Instantly...

TTPH - La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.

SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening disease...
TTPH - La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.

La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases SAN DIEGO, Ca...
TTPH - Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta

Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA TM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an uns...